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arubstantial progress has been made in the awareness,
treatment, and prevention of cardiovascular disease
(CVD) in women since the first women-specific clin-
al recommendations for the prevention of CVD were
blished by the American Heart Association (AHA) in 1999
). The myth that heart disease is a “man’s disease” has been
bunked; the rate of public awareness of CVD as the leading
use of death among U.S. women has increased from 30% in
97 to 54% in 2009 (2). The age-adjusted death rate
sulting from coronary heart disease (CHD) in females,
hich accounts for about half of all CVD deaths in women,
as 95.7 per 100,000 females in 2007, a third of what it was
1980 (3,4). Approximately 50% of this decline in CHD
aths has been attributed to reducing major risk factors and
e other half to treatment of CHD including secondary
eventive therapies (4). Major randomized controlled clini-
l trials such as the Women’s Health Initiative have changed
e practice of CVD prevention in women over the past
cade (5). The investment in combating this major public
alth issue for women has been significant, as have the
ientific and medical achievements.
Despite the gains that have been made, considerable
allenges remain. In 2007, CVD still caused 1 death per
inute among women in the United States (6). These repre-
nt 421,918 deaths, more women’s lives than were claimed
cancer, chronic lower respiratory disease, Alzheimer
sease, and accidents combined (6). Reversing a trend of the
st 4 decades, CHD death rates in U.S. women 35 to 54
ars of age now actually appear to be increasing, likely
cause of the effects of the obesity epidemic (4). CVD rates
the United States are significantly higher for black females
mpared with their white counterparts (286.1/100,000 ver-
s 205.7/100,000). This disparity parallels the substantially
wer rate of awareness of heart disease and stroke that has
en documented among black versus white women (2,6–8).
f concern is that in a recent AHA national survey, only 53%
women said the first thing they would do if they thought
ey were having a heart attack was to call 9-1-1. This
stressing lack of appreciation by many women for the need
r emergency care for acute cardiovascular events is a barrier
optimal survival among women and underscores the need
r educational campaigns targeted to women (2).
CVD rates in the United States are significantly higher for
ack females compared with their white counterparts (286.1/
0,000 versus 205.7/100,000), which parallels the substan-
ally lower rate of awareness of heart disease and stroke that
s been documented among black versus white women
,6–8). Each year, 55,000 more women than men have a
roke. Atrial fibrillation is independently associated with a 4-
5-fold increased risk of ischemic stroke and is responsible blr 15% to 20% of all ischemic strokes. It has been shown
at undertreatment with anticoagulants doubles the risk of
current stroke; therefore, the expert panel voted to include
commendations for the prevention of stroke among women
ith atrial fibrillation (6,9,10).
Adverse trends in CVD risk factors among women are an
going concern. After 65 years of age, a higher percentage
women than men have hypertension, and the gap will
kely increase with the continued aging of the female
pulation (6). The prevalence of hypertension in blacks in
e United States is among the highest in the world, and it is
creasing. From 1988 to 1994 through 1999 to 2002, the
evalence of hypertension in adults increased from 35.8% to
.4% among blacks, and it was particularly high among
ack women at 44.0% (11).
A very ominous trend is the ongoing increase in average
dy weight, with nearly 2 of every 3 U.S. women 20 years
age now overweight or obese (6). The rise in obesity is a
y contributor to the burgeoning epidemic of type 2 diabetes
ellitus now seen in 12 million U.S. women. Furthermore,
e rate of diabetes mellitus is more than double in Hispanic
omen compared with non-Hispanic white women (12.7%
rsus 6.45%, respectively) (6). The increasing prevalence of
abetes mellitus is concerning for many reasons, especially
r its association with a greatly increased overall risk of
yocardial infarction (MI) and stroke (12).
The challenge of CVD in women is not limited to the
nited States. Recent data document the global scope of the
oblem: Heart disease is the leading cause of death in
omen in every major developed country and most emerging
onomies (13).
Given the worldwide health and economic implications of
VD in women, there is strong rationale to sustain efforts to
ntrol major CVD risk factors and to apply evidence-based
erapies in women.
In 2004, the AHA, in collaboration with numerous other
ganizations, expanded its focus on female-specific clinical
commendations and sponsored the “Evidence-Based
uidelines for Cardiovascular Disease Prevention in
omen” and updated them in 2007 (14,15). Initially, the
idelines challenged the conventional wisdom that women
ould be treated the same as men, primarily related to
ncerns about the lack of representation of women in
inical trials. As more women have participated in CVD
search studies and more gender-specific analyses have been
blished, data have become available to make more defini-
ve recommendations. Evolving science suggests that the
erwhelming majority of recommendations to prevent CVD
e similar for women and men, with few exceptions. Nota-
y, aspirin is routinely recommended for the primary pre-
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Guidelines for the Prevention of CVD in Women—2011 Update March 22, 2011:1404–23ntion of MI in men but not women (16,17). However, there
a growing appreciation that there may be gender differences
the magnitude of the relative and absolute potential
nefits and risks of preventive interventions. The panel
knowledged unique opportunities to identify women at risk
.g., pregnancy) and addressed concerns that women often
ve more comorbidities and are older than men when they
perience CHD.
The current guidelines encompass prevention of the scope
atherosclerotic thrombotic cardiovascular outcomes in
omen. However, it should be noted that the majority of data
ed to develop these guidelines is based on trials of CHD
evention. Future guidelines should consider recommenda-
ons for specific outcomes of particular importance in
omen, such as stroke. Each year, 55,000 more women die of
roke than men, and before 75 years of age. Stroke accounts
r a higher proportion of CVD events than CHD in females,
hereas the ratio is the opposite for males. Women have
ique risk factors for stroke such as pregnancy and hormone
erapy, have a greater prevalence of hypertension in older
es, a major risk factor for stroke, and may have different
nefits and risks associated with interventions to reduce
roke risk compared with men (6). Atrial fibrillation is
dependently associated with a 4- to 5-fold increased risk of
chemic stroke and is responsible for 15% to 20% of all
chemic strokes. It has been shown that undertreatment with
ticoagulants doubles the risk of recurrent stroke; therefore,
e expert panel voted to include recommendations for the
evention of stroke among women with atrial fibrillation
,9,10).
Current systematic and critical review of the literature
ntinues to update the guidelines, which have become the
undation to inform national educational programs for
althcare professionals and women consumers of healthcare.
major evolution from previous guidelines to the 2011
date is that effectiveness (benefits and risks observed in
inical practice) of preventive therapies was strongly con-
dered and recommendations were not limited to evidence
at documents efficacy (benefits observed in clinical re-
arch); hence, in the transformation from “evidence-based”
“effectiveness-based” guidelines for the prevention of
rdiovascular disease in women, the panel voted to update
commendations to those therapies that have been shown to
ve sufficient evidence of clinical benefit for CVD out-
mes. Class III recommendations from prior guidelines that
e not recommended for use for the prevention of CVD
able 1) were retained as no new evidence has become
ailable to alter the recommendations. The list of Class III
commendations is not exhaustive, and therapies that were
eviously searched were based on those preventive interven-
ons commonly believed to have a potential benefit for the
evention of CVD in women despite a lack of definitive
inical trial evidence of benefit. Uses of medications for
dications beyond the prevention of ischemic CVD are not
dressed in this document. Some interventions (e.g.,
reening for depression) were recognized to lack data on
rect CVD outcomes benefit but were included in an
gorithm for approaches to the evaluation of women
cause they may indirectly impact CVD risk through anherence to prevention therapies or other mechanisms
igure 1). The expert panel also recognized that cost-
fectiveness, which may differ by sex, needed to be
dressed; thus, a comprehensive review of current liter-
ure on the topic has been added. The guidelines continue
prioritize lifestyle approaches to the prevention of CVD,
kely the most cost-effective strategy. The panel also
knowledged that difficulty in adhering to lifestyle and
edical recommendations limits effectiveness; therefore,
w sections were added on guideline implementation.
VD Risk Assessment
the 2007 update, a new algorithm for risk classification in
omen was adopted that stratified women into 3 categories:
t high risk,” based on the presence of documented CVD,
abetes mellitus, end-stage or chronic kidney disease, or
-year predicted risk for CHD 20%; “at risk,” given the
esence of1 major CVD risk factors, metabolic syndrome,
idence of subclinical vascular disease (e.g., coronary cal-
fication), or poor exercise tolerance on treadmill testing;
d “at optimal risk” in the setting of a Framingham risk
ore 10%, absence of major CVD risk factors, and
gagement in a healthy lifestyle. This approach to risk
assification in women was based on several observations: 1)
he lifetime risk for CVD is high in almost all women and
proaches 1 in 2 on average, so prevention is important in all
omen (18); 2) most clinical trial data used to formulate the
commendations included either women at high risk because
known CVD or apparently healthy women with a spectrum
risk, which allowed the scheme to align the guidelines with
e evidence; and 3) the appreciation of the limitations of
andard risk stratification schemes such as the Framingham
sk score is growing. These limitations include the narrow
cus on only short-term (10-year) risk and on only MI and
HD death, the lack of inclusion of family history, overesti-
ation or underestimation of risk in nonwhite populations,
ble 1. Class III Interventions (Not Useful/Effective and May
e Harmful) for the Prevention of CVD in Women
enopausal therapy
ormone therapy and selective estrogen-receptor modulators (SERMs)
ould not be used for the primary or secondary prevention of CVD
lass III, Level of Evidence A).
ntioxidant Supplements
ntioxidant vitamin supplements (e.g., vitamin E, C, and beta carotene)
ould not be used for the primary or secondary prevention of CVD
lass III, Level of Evidence A).
lic Acid*
lic Acid, with or without B6 and B12 supplementation, should not be
ed for the primary or secondary prevention of CVD (Class III, Level of
idence A).
spirin for MI in women <65 years of age
outine use of aspirin in healthy women 65 years of age is not
commended to prevent MI (Class III, Level of Evidence B).
CVD indicates cardiovascular disease; MI, myocardial infarction.
*Folic acid supplementation should be used in the childbearing years to
event neural tube defects.d the fact that subclinical CVD can have relatively high
Fi
H
an
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March 22, 2011:1404–23 Guidelines for the Prevention of CVD in Women—2011 Updategure 1. Flow diagram for CVD preventive care in women. CVD indicates cardiovascular disease; DASH, Dietary Approaches to Stop
ypertension; CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
d ACS, acute coronary syndrome.
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Guidelines for the Prevention of CVD in Women—2011 Update March 22, 2011:1404–23evalence among women who are scored as being at low risk
,19).
The 2007 panel believed that a Framingham 10-year
edicted risk for CHD 20% could be used to identify a
oman at high risk but that a lower score was not sufficient
ensure that an individual woman was at low risk. Thus, the
gorithm included consideration of factors beyond the 10-
ar predicted risk for CHD used in current National Cho-
sterol Education Panel guidelines of lipid management (20).
he panel emphasized that healthcare professionals should
ke several factors into consideration beyond just the Fra-
ingham risk score, including medical and lifestyle history,
mily history of CVD, markers of preclinical disease, and
her conditions, as they make decisions about the intensity of
eventive therapy.
Since the 2007 update, a number of lines of evidence have
erged to support the risk classification algorithm adopted
2007. Hsia et al. (21) directly evaluated the algorithm in
1,808 women 50 to 79 years of age who were enrolled in
e Women’s Health Initiative and followed up for a mean of
8 years. When the 2007 update categories were applied,
% of women were found to be at high risk, 72% were at
sk, and 4% were at optimal risk (21). Of note, 13% of
omen could not be classified by the 2007 algorithm because,
though they lacked risk factors, they did not adhere to a
althy lifestyle.
Among high-risk, at-risk, optimal risk, and unclassified
omen, the rates of MI, CHD death, or stroke were 19.0%,
5%, 2.2%, and 2.6% per 10 years, respectively (p for trend
0.0001) (20). Although absolute event rates differed among
omen of different race/ethnic groups, the 2007 risk classi-
cation algorithm appropriately ordered event rates in all
oups, with a 7- to 20-fold difference in event rates between
timal-risk and high-risk women. The 2007 update algo-
thm discriminated those who experienced coronary events
ith accuracy similar to current National Cholesterol Educa-
on Panel Adult Treatment Panel III risk categories (10%,
% to 20%, and 20%) based on Framingham 10-year
edicted risks (20).
Therefore, the current panel elected to continue this general
proach to risk classification in women for the 2011 guide-
nes with some modifications (Table 2). First, the AHA
cently defined a new concept of “ideal cardiovascular
alth” defined by the absence of clinical CVD and the
esence of all ideal levels of total cholesterol (200 mg/dL),
ood pressure (120/80 mm Hg), and fasting blood glucose
100 mg/dL), as well as adherence to healthy behaviors,
cluding having a lean body mass index (25 kg/m2),
stinence from smoking, participation in physical activity at
commended levels, and pursuit of a Dietary Approaches to
top Hypertension–like eating pattern (22). When achieved
maintained into middle age, the overall pattern of ideal
rdiovascular health is associated with greater longevity;
amatic reductions in short-term, intermediate-term, and
fetime risks for CVD events; greater quality of life in older
es; and lower Medicare costs at older ages (22). It should
so be noted that several factors, which have been associated
ith an increased risk of CVD in women, have been identi- hsed, but their utility for screening and improving clinical
tcomes has not been determined.
Other modifications to the risk classification algorithm
clude acknowledgement of the availability of several 10-
ar risk equations for the prediction of 10-year global CVD
sk such as the updated Framingham CVD risk profile and
e Reynolds risk score for women (23,24). The panel
nsidered that either of these scores would be appropriate
r use, particularly given their inclusion of CVD events
yond just CHD, but did not endorse routine screening with
gh-sensitivity C-reactive protein (hsCRP), which would be
quired for use of the Reynolds risk score, because there are
data to support the association between a reduction in
ble 2. Classification of CVD Risk in Women
sk Status Criteria
gh risk (1
gh-risk states)
Clinically manifest CHD
Clinically manifest cerebrovascular disease
Clinically manifest peripheral arterial disease
Abdominal aortic aneurysm
End-stage or chronic kidney disease
Diabetes mellitus
10-y Predicted CVD risk 10%
risk (1 major
k factor[s])
Cigarette smoking
SBP 120 mm Hg, DBP 80 mm Hg, or treated
hypertension
Total cholesterol 200 mg/dL, HDL-C 50 mg/dL,
or treated for dyslipidemia
Obesity, particularly central adiposity
Poor diet
Physical inactivity
Family history of premature CVD occurring in first-
degree relatives in men 55 y of age or in
women 65 y of age
Metabolic syndrome
Evidence of advanced subclinical atherosclerosis
(e.g., coronary calcification, carotid plaque, or
thickened IMT)
Poor exercise capacity on treadmill test and/or
abnormal heart rate recovery after stopping
exercise
Systemic autoimmune collagen-vascular disease
(e.g., lupus or rheumatoid arthritis)
History of preeclampsia, gestational diabetes, or
pregnancy-induced hypertension
eal cardiovascular
alth (all of these)
Total cholesterol 200 mg/dL (untreated)
BP 120/80 mm Hg (untreated)
Fasting blood glucose 100 mg/dL (untreated)
Body mass index 25 kg/m2
Abstinence from smoking
Physical activity at goal for adults 20 y of age:
150 min/wk moderate intensity, 75 min/wk
vigorous intensity, or combination
Healthy (DASH-like) diet (see Appendix)
CVD indicates cardiovascular disease; CHD, coronary heart disease; SBP,
stolic blood pressure; DBP, diastolic blood pressure; HDL-C; high-density
oprotein cholesterol; IMT, intima-media thickness; BP, blood pressure; and
SH, Dietary Approaches to Stop Hypertension.CRP and improved clinical outcomes. Numerous other
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March 22, 2011:1404–23 Guidelines for the Prevention of CVD in Women—2011 Updateultivariable risk scores exist and may be clinically useful if
sed on a population and on end points relevant to the
tient in question (25–27). In this context, the current
idelines recommend use of a new cut point for defining
gh risk as 10% 10-year risk for all CVD, not just CHD
one.
Recent analyses of clinical trial data suggest that at
proximately this threshold statin therapy is associated with
gh cost-effectiveness (and possibly cost savings) in the era
generic statins (28). In addition, the recent Justification for
se of Statins in Prevention, an Intervention Trial Evaluating
osuvastatin (JUPITER) in primary prevention populations
monstrated the efficacy of statin medications in lowering
obal CVD event risk, including among women, although
e absolute benefit was small and the number needed to treat
prevent a major CVD event was greater than in men (29).
Several lines of evidence support the focus of women’s
idelines on long-term risk for CVD rather than solely on
-year risk for CHD. First, observational and clinical trial
ta indicate that women’s risks for stroke and heart failure
rough middle and older age typically exceed their risk for
HD, in contrast to the pattern observed in men, for whom
HD risk increases earliest (30,31). Thus, the focus in the
rrent National Cholesterol Education Panel Adult Treat-
ent Panel III guidelines on 10-year CHD risk may substan-
ally underestimate clinically relevant overall CVD risk and
erefore tends to preclude the warranted, intensive preven-
ve measures for most high-risk women (32).
Indeed, it is difficult for a woman 75 years of age, even
ith several markedly elevated risk factors, to exceed a 10%
et alone a 20%) 10-year predicted risk for CHD with the
dult Treatment Panel III risk estimator (33,34). Thus, few
omen qualify for aggressive CVD prevention when 10-year
sk is used to determine its need. Fortunately, more recent
ramingham equations are now available to predict 10- and
-year risk for all CVD events (including CHD, stroke, heart
ilure, and claudication) (34–36).
A focus on long-term CVD risk, not solely on 10-year
HD risk, is also supported by recent data indicating that
% of American adults (87 million people), including 47.5
illion women overall and 64% of women 60 to 79 years of
e, have a 10-year predicted risk for CHD of 10% but a
edicted lifetime risk for CVD of 39% (37).
The role that novel CVD risk biomarkers (e.g., hsCRP or
vanced lipid testing) and imaging technologies (e.g., coro-
ry calcium scoring assessment) should play in risk assess-
ent and in delineation of appropriate preventive interven-
ons is not yet well defined. It should be noted that JUPITER
d not test a strategy of routine screening with hsCRP to
termine benefit of statin therapy because those with lower
CRP levels were not studied (29). These approaches should
t be used for routine screening of all women. Instead, the
HA and other national groups have recommended that the
e of these novel modalities should be reserved for refining
sk estimates in intermediate-risk patients when there is
certainty about the need to start drug therapy (38–41).
urther research is needed on added benefits, risks, and costs
sociated with such strategies. Although recent evidence
ggests that using imaging modalities such as coronary thlcium scoring and carotid ultrasound to demonstrate the
esence of advanced atherosclerosis has the greatest utility
r reclassifying risk in those (including women) predicted to
at intermediate risk on the basis of short-term risk
uations such as the Framingham risk score, their value in
proving clinical outcomes has not been established (42,43).
should also be noted that several novel risk factors, which
ve been associated with an increased risk of CVD in
omen, have been identified, but their utility for screening
d improving clinical outcomes has not been determined.
Because of its unique cardiovascular and metabolic stress,
egnancy provides a unique opportunity to estimate a wom-
’s lifetime risk. For example, preeclampsia may be an early
dicator of CVD risk (44,45). A recent large meta-analysis
und that women with a history of preeclampsia have
proximately double the risk for subsequent ischemic heart
sease, stroke, and venous thromboembolic events over the 5
15 years after pregnancy (46). In these patients, the
ysiological “metabolic syndrome of pregnancy” may pro-
ke pregnancy complications. The latter could be considered
“failed stress test,” possibly unmasking early or preexisting
dothelial dysfunction and vascular or metabolic disease
7). Therefore, appropriate referral postpartum by the obste-
ician to a primary care physician or cardiologist should
cur so that in the years after pregnancy, risk factors can be
refully monitored and controlled. Healthcare professionals
ho meet women for the first time later in their lives should
ke a careful and detailed history of pregnancy complica-
ons with focused questions about a history of gestational
abetes mellitus, preeclampsia, preterm birth, or birth of an
fant small for gestational age (48–50).
Future research should evaluate the potential for exposures,
ents, or interaction with the medical system during periods
potential vulnerability across a woman’s lifespan such as
enarche, pregnancy, and menopause to identify women at
sk and to determine the effectiveness of diagnostic and
eventive interventions during these critical times.
Other factors that are more prevalent among women and/or
ay make special contributions to CVD risk in women need
rther clarification in the context of defining effective inter-
ntions to improve CVD outcomes, as well as functional
tcomes and adherence to therapy. These include depression
d other psychosocial risk factors, as well as autoimmune
seases. Systemic lupus erythematosus and rheumatoid ar-
ritis may be unrecognized risk factors in women and have
en associated with a significantly increased relative risk for
VD (51). Women with such conditions but without clini-
lly evident CVD should be considered at risk and screened
r CVD risk factors, whereas women with prior CVD events
ould be screened for these conditions to allow appropriate
condary CVD prevention efforts and to allow the autoim-
une condition to be addressed.
iversity, Disparities, and
opulation Representation
he changing demographics of the United States, and indeed
e world, necessitate that healthcare professionals consider
e diversity of the patients that they encounter. Diversity
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althcare team. In addition to the well-recognized classifi-
tions of race/geographic origin and ethnic origin, other
cets of diversity need to be considered such as age,
nguage, culture, literacy, disability, frailty, socioeconomic
atus, occupational status, and religious affiliation, among
hers. A better understanding of these aspects of diversity
ay help to reduce disparities in healthcare delivery. The
stitute of Medicine defines disparity as a difference in
eatment provided to members of ethnic or racial groups that
not justified by health condition differences or treatment
eferences. The Institute of Medicine report also states that
ese disparities exist even when controlling for insurance
atus, socioeconomic status, and comorbidities (52). Dispar-
ies in cardiovascular health continue to be a serious public
alth issue in the United States. Despite the remarkable
clines in cardiovascular mortality observed nationally over
e past few decades, many population subgroups defined by
ce, ethnicity, gender, socioeconomic status, educational
vel, or geography, still show striking disparities in cardio-
scular health. The pervasive nature of these disparities and
mpelling evidence of the adverse impact they have on
inical outcomes and quality of life in black and Hispanic
omen need to be recognized by clinicians. The root causes
disparities include variations and lack of understanding of
alth beliefs, cultural values and preferences, and patients’
ability to communicate symptoms in a language other than
eir own, among other factors (53–55). During the past
cade, the clinical research focus on innovative methods to
iminate healthcare disparities has demonstrated some prom-
e in multiteam culturally tailored interventions such as those
ith nurse-led case managers and community health workers.
ultural competence, therefore, has emerged as a process that
ites the assessment and recognition of cultural differences,
ltural knowledge, and cultural skills (56). Culturally sensi-
ve care includes the adaptation of healthcare delivery to
eet the needs of a diverse patient population. Thus, diver-
ty, as defined above, in the context of healthcare, is
ncerned with delivering equitable care for all individuals
7–59).
Although guidelines may be applied across all groups, it is
portant to remember the higher prevalence of risk factors
certain racial/ethnic groups such as hypertension among
ack women or diabetes mellitus in women of Hispanic
scent (6). Notably, the highest coronary heart death rates
d the highest overall CVD morbidity and mortality occur in
ack women. Furthermore, the mortality from coronary
tery disease for black women is similar to that of white men
). These disparities in the occurrence of CVD and estab-
shed risk factors underscore the need for heightened pre-
ntive efforts in subpopulations of women.
Ethnic categorization often fails to recognize cultural
fferences such as within Hispanics. Although the broad term
“Latino” or “Hispanic,” the actual definition includes
ople of Cuban, Mexican, Puerto Rican, or South or Central
merican origin. These cultures have distinct backgrounds,
alth behaviors, and beliefs, but they are often grouped
gether. Hispanics living in the United States may be faced
ith stresses of immigration, lower socioeconomic status, tid inadequate access to healthcare. Despite these adversi-
es, Hispanics, with a burden of cardiovascular risk factors
milar to that of non-Hispanic whites, have a lower mortal-
y. This observation has been called the “Hispanic paradox”
confirmed in recent data released by the National Center
r Health Statistics, which finds Hispanic life expectancy to
80 years compared with 77.5 years for non-Hispanic
hites and 72.3 years for non-Hispanic blacks (60,61).
lthough deaths from heart disease have decreased in all
oups, Hispanics have the lowest percentage of cardiovas-
lar deaths (21.7%) compared with non-Hispanics (26.3%)
2). The life expectancy for Hispanic women was the highest
r all groups at 83.1 years compared with 80.4 years for
n-Hispanic white women, 76.2 years for non-Hispanic
ack women, 77.9 years for Hispanic men, and 75.6 years for
n-Hispanic white men. The lowest life expectancy was for
n-Hispanic black men at 69.2 years (63).
In addition to racial and ethnic diversity, the healthcare
ofessional should be familiar with the patient’s socioeco-
mic status, which may make attaining healthy lifestyles and
ing medications more difficult. In this context, recommen-
tions that are more appropriate to the life circumstances of
e patient may have to be adapted. Age should also be
nsidered in the context of diversity because in the life
ntinuum of women, application of the guidelines may need
aptation to stages such as pregnancy or the frailty of the
derly. Thus, the recognition of all aspects of diversity and
e delivery of culturally sensitive care must guide clinicians
apply these guidelines broadly to match the diversity
women patients they treat, avoiding disparity of care
4 – 66).
ternational Issues
he international applicability of these guidelines is a critical
sue because CVD has become a global pandemic among
omen. Approximately 81% of all CVD deaths in women
cur in low- and middle-income countries with limited
pacity for guidelines development (67). International appli-
bility can be defined as the desirability and capacity to
opt the recommendations proposed in this guidelines doc-
ent “as is” or after appropriate adaptation by medical
cieties, clinicians, and patients in other countries.
The World Health Organization and other international
ganizations have proposed measures for evaluating the
ternational applicability of a guidelines document (68–72).
the Global Program on Evidence for Health Policy.
uidelines for WHO Guidelines, 4 criteria were proposed for
sessing the international applicability of guidelines: 1)
ficacy and safety, 2) cost-effectiveness, 3) affordability, and
population benefits (68). The Appraisal of Guidelines
esearch and Evaluation project, an international collabora-
on, also designed an instrument to appraise clinical guide-
nes (69). The indicators for applicability assessment include
tential organizational barriers in applying the guidelines,
st implications of applying the recommendations, and the
esence of key review criteria for monitoring and audit
rposes (70). Methods and tools are available for interna-onal users to determine whether recommendations provided
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me modifications are needed before application of guide-
nes (70–75).
International applicability is an important feature of the
dated women’s guidelines because almost all of the rec-
mendations can be used in most countries or regions,
ther directly or with slight modifications. The descriptions
the recommendations are easy to comprehend and apply in
inical practice. Risk classification is practical and should be
asible for clinicians and patients worldwide. Additionally,
neric drugs are available for most of the therapies recom-
ended in this guidelines document. Some modifications,
wever, may be required, depending on the specific de-
ands of the countries or regions such as the definition of
neralized overweight obesity and central obesity.
It is noteworthy that some of the recommendations in the
idelines for CVD prevention in women are based on
udies with relatively small sample sizes of women, which is
rticularly problematic when considering women with dif-
rent cultural and racial-ethnic backgrounds. Thus, the con-
usions of meta-analyses based on these studies may not be
neralizable to women worldwide.
ealthcare Professional Implementation
chievement of both the desired degree and persistence of
VD preventive care has been disappointing in both women
d men. Although improving, the level of public awareness
d rates of treatment and control of lipids, hypertension, and
abetes mellitus remain suboptimal (76–78). For instance,
50% of Americans with hypertension are not treated to
al. Furthermore, ethnic/racial disparities in the manage-
ent of hypertension, lipids, and diabetes mellitus persist (76).
By establishing scientific levels of evidence and desired
eatment strategies, guidelines are fundamental to improving
VD preventive care. However, multiple patient, clinician,
d systemic barriers limit adherence to CVD prevention
idelines for women (79,80). A meta-analysis of 100
edical adherence studies shows that women are as likely to
nonadherent to medical therapies as men (81). It is ironic
at the level of scientific evidence incorporated in most
idelines is much more robust than the research available for
actical implementation and maintenance of adherence to
ose guidelines. Multiple barriers hinder adoption of guide-
nes, including lack of access to primary care services and
ck of knowledge and skill in guideline implementation on
e part of internists, family practitioners, and gynecologists
2,83). For instance, in a study of impediments to CVD
evention, one half of obstetrician-gynecologists and one
ird of internists surveyed were unaware that tobacco use is
e leading cause of MIs in younger women (84).
The physicians who reported time as a barrier were less
kely to discuss smoking cessation with their women patients
3). Impediments to implementation of guidelines include
me pressures, lack of organizational support, and patient
sistance to behavioral change (84,85). Conclusions about
e best methods for implementation of CVD prevention have
en difficult to reach because of heterogeneity in interven-ons and outcomes between studies and other methodological remitations (84,85). The preponderance of evidence suggests
at unidimensional interventions such as brief initial patient
ucation and traditional patient reminders are generally
effective (84,85). The most robust interventions are multi-
ceted, are interactive, and incorporate decision systems and
edback (84,85).
An intervention increasingly advocated improving guide-
nes adherence is “pay for performance.” Performance mea-
res are available for primary prevention of CVD, and the
terature suggests some improvement in healthcare profes-
onal adherence to healthcare quality measures when pay-
r-performance policies are implemented (86,87). Unfortu-
tely, however, because of reliance on patient outcomes,
ch policies may also result in unintended detrimental
nsequences such as reduced access to care for sicker
tients (87). Similar to the literature supporting guidelines
herence in general, much more research is needed on best
actices, benefits, and hidden costs of pay-for-performance
itiatives, including whether performance measures some-
mes increase disparities in care.
Improvement in adherence to CHD guideline has been
cumented in centers implementing the Get With The
uidelines program of the AHA (88). Of note, disparities in
I guidelines adherence by gender, age, ethnicity, and race
peared to narrow over time in hospitals instituting this
ogram (88,89). The AHA is now initiating a Get With The
uidelines–Outpatient program, and the American College of
ardiology has embraced quality improvement activities in
plementation of CVD prevention guidelines.
The evidence base for practical methods for improving
ideline adherence by effectively addressing substantive
tient, clinician, and system-level barriers is generally lack-
g; however, there is some cause for optimism. There is
creasing patient and clinician knowledge of the importance
CHD in women, and there have been improvements in
VD risk factor awareness, treatment, and control (89).
Achieving the goal of improving cardiovascular health
hile reducing death and disability from CVD and stroke in
omen will require concerted efforts toward further research
d the dissemination and implementation of lifestyle and
eatment interventions. In the interim, quality improvement
forts can focus on incorporating multidimensional, interac-
ve systems to increase accountability among payers, health-
re professionals, and patients for cardiovascular preventive
re in women (90).
atient and Public Education
2000, it was estimated that only 7% of people with CHD
hered to prescribed treatments for CVD lifestyle risk
ctors (91). Studies evaluating adherence to medical thera-
es for CVD prevention also show similarly low rates of
rsistence. In addition, it is estimated that people with
ronic illnesses may see up to 16 different physicians
nually, making adherence reinforcement even more chal-
nging for patients and healthcare professionals (92,93).
hirty percent to 70% of all hospital admissions for
edication-related illness are attributed to poor adherence,
sulting in billions of dollars in additional healthcare costs
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es is of utmost importance (94,95). Effective implementation
national guidelines for the primary prevention of CVD will
quire a team-based approach to education that includes the
tient, the family, and key healthcare professionals (93).
The Joint Commission emphasizes the importance of
tient education that is directed at improving patient out-
mes, including quality of life (96). National guidelines for
e primary prevention of CVD rely on patient education to
pport the importance of lifestyle change and medication
herence to reduce acute MI and stroke (32,97). Providing
ccessful patient education is challenging for clinicians
cause of many factors, including limited time for healthcare
sits, patients with complex comorbidities, lack of staff for
aching and follow-up, lack of training in counseling patients
out behavior change, and lack of reimbursement for pre-
ntion in general and patient education in particular (98).
atient-related nonadherence is common and is most preva-
nt in several circumstances, including low socioeconomic
atus, low literacy level, depression and other psychiatric
lnesses, older age, poor hearing or vision, poor cognitive
nction, and lack of fluency in English, as well as in certain
ltures and religions in which confidence in and cooperation
ith Western medicine may be limited.
Understanding effective educational theories/practices can
prove the ability of clinicians to effect behavior change and
herence to therapies. Well-recognized approaches include
haviorally based individual counseling, “motivational in-
rviewing,” “self-efficacy,” and “stages of readiness for
ange” (99–101). Self-monitoring (e.g., food records, blood
essure/blood glucose logs), group sessions/shared medical
sits (e.g., for newly diagnosed diabetes mellitus), computer-
sisted reminders, and other electronic communication to
pport behavioral change have been shown to improve both
festyle and medication adherence (102–106). Involving the
tient and the patient’s family in setting appropriate short-
rm achievable goals with frequent follow-up will also
hance success.
These guidelines call for a renewed focus on health
ucation, including systematic follow-up to assess effective-
ss of medical and lifestyle therapies. Assessment of barriers
adherence and interventions to address them must be
tegrated into clinical practice, and barriers specific for
omen must be considered. Barriers hindering adherence to
VD prevention recommendations are common among
omen and include family and caretaking responsibilities,
ress, sleep deprivation, fatigue, and lack of personal time.
ducational efforts are critically important, because increased
areness of personal cardiovascular risk factors has been
sociated with improved health and lifestyles for women and
eir family members (107).
ethods
election of Expert Panel
he AHA Manuscript Oversight Committee commissioned
e update of the guidelines and approved the writing group
air, the executive writing committee members with specificpertise (methods and cost-effectiveness, risk assessment,
althcare professional implementation, patient and con-
mer education, diversity and population representation, and
ternational issues), and expert panel members to review the
terature for updates to the recommendation topic areas. The
adership of each AHA scientific council was asked to
minate a recognized expert in CVD prevention who had
rticular knowledge about women.
Major professional or government organizations with a
ission consistent with CVD prevention were solicited to
rve as cosponsors and were asked to nominate 1 represen-
tive with full voting rights to serve on the expert panel.
ach executive writing committee and expert panel member
mpleted a conflict of interest statement and was asked to
stain from discussion or voting on any recommendations
emed to be a potential conflict of interest. Panelists also
ggested diverse professional and community organizations
endorse the final document after its approval by the AHA
cience Advisory and Coordinating Committee and cospon-
ring organizations.
election of Topics and Systematic Search
he expert panel reviewed the list of recommendations in the
07 guidelines and suggested additional topics to be
arched to determine if they warranted discussion or a
inical recommendation. The search terms for the systematic
arch were similar to those conducted in 2007 and previ-
sly described (14,15). The databases searched for this
date were PubMed, Embase, and Cochrane. The timeframe
r the updated search was January 2006 through January
10. Briefly, studies were included if they were randomized
inical trials or large prospective cohort studies (1,000
bjects) of CVD risk–reducing interventions, meta-analyses
at used a quantitative systematic review process, or surro-
te end-point studies with at least 10 cases of major clinical
VD end points reported. The systematic search was con-
cted by the AHA librarian. Class III recommendations
ble 3. Classification and Levels of Evidence
assification
d Level of
idence Strength of Recommendation
assification
Class I Intervention is useful and effective
Class IIa Weight of evidence/opinion is in favor of
usefulness/efficacy
Class IIb Usefulness/efficacy is less well established by evidence/
opinion
Class III Procedure/test not helpful or treatment has no proven
benefit
Procedure/test excess cost without benefit or harmful or
treatment harmful to patients
vel of
idence
A Sufficient evidence from multiple randomized trials
B Limited evidence from single randomized trial or other
nonrandomized studies
C Based on expert opinion, case studies, or standard of care
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festyle Interventions
Cigarette smoking
Women should be advised not to smoke and to avoid environmental tobacco smoke. Provide counseling at each encounter, nicotine replacement, and other
pharmacotherapy as indicated in conjunction with a behavioral program or formal smoking cessation program (Class I; Level of Evidence B).
Physical activity
Women should be advised to accumulate at least 150 min/wk of moderate exercise, 75 min/wk of vigorous exercise, or an equivalent combination of
moderate- and vigorous-intensity aerobic physical activity. Aerobic activity should be performed in episodes of at least 10 min, preferably spread throughout
the week (Class I; Level of Evidence B).
Women should also be advised that additional cardiovascular benefits are provided by increasing moderate-intensity aerobic physical activity to 5 h
(300 min)/wk, 2 1/2 h/wk of vigorous-intensity physical activity, or an equivalent combination of both (Class I; Level of Evidence B).
Women should be advised to engage in muscle-strengthening activities that involve all major muscle groups performed on 2 d/wk (Class I; Level of
Evidence B).
Women who need to lose weight or sustain weight loss should be advised to accumulate a minimum of 60 to 90 min of at least moderate-intensity physical
activity (e.g., brisk walking) on most, and preferably all, days of the week (Class I; Level of Evidence B).
Cardiac rehabilitation
A comprehensive CVD risk-reduction regimen such as cardiovascular or stroke rehabilitation or a physician-guided home- or community-based exercise
training program should be recommended to women with a recent acute coronary syndrome or coronary revascularization, new-onset or chronic angina,
recent cerebrovascular event, peripheral arterial disease (Class I; Level of Evidence A) or current/prior symptoms of heart failure and an LVEF 35%
(Class I; Level of Evidence B).
Dietary intake
Women should be advised to consume a diet rich in fruits and vegetables; to choose whole-grain, high-fiber foods; to consume fish, especially oily fish,
at least twice a week; to limit intake of saturated fat, cholesterol, alcohol, sodium, and sugar; and avoid trans-fatty acids. See Appendix (Class I;
Level of Evidence B).
Note: Pregnant women should be counseled to avoid eating fish with the potential for the highest level of mercury contamination (e.g., shark, swordfish,
king mackerel, or tile fish).
Weight maintenance/reduction
Women should maintain or lose weight through an appropriate balance of physical activity, caloric intake, and formal behavioral programs when indicated to
maintain or achieve an appropriate body weight (e.g., BMI 25 kg/m2 in U.S. women), waist size (e.g., 35 in), or other target metric of obesity.
(Class I; Level of Evidence B).
Omega-3 fatty acids
Consumption of omega-3 fatty acids in the form of fish or in capsule form (e.g., EPA 1800 mg/d) may be considered in women with hypercholesterolemia
and/or hypertriglyceridemia for primary and secondary prevention (Class IIb; Level of Evidence B).
Note: Fish oil dietary supplements may have widely variable amounts of EPA and DHA (likely the only active ingredients).
ajor risk factor interventions
Blood pressure: optimal level and lifestyle
An optimal blood pressure of 120/80 mm Hg should be encouraged through lifestyle approaches such as weight control, increased physical activity,
alcohol moderation, sodium restriction, and increased consumption of fruits, vegetables, and low-fat dairy products (Class I; Level of Evidence B).
Blood pressure: pharmacotherapy
Pharmacotherapy is indicated when blood pressure is 140/90 mm Hg (130/80 mm Hg in the setting of chronic kidney disease and diabetes mellitus).
Thiazide diuretics should be part of the drug regimen for most patients unless contraindicated or if there are compelling indications for other agents in
specific vascular diseases. Initial treatment of high-risk women with acute coronary syndrome or MI should be with -blockers and/or ACE inhibitors/ARBs,
with addition of other drugs such as thiazides as needed to achieve goal blood pressure (Class I; Level of Evidence A).
Note: ACE inhibitors are contraindicated in pregnancy and ought to be used with caution in women who may become pregnant.
Lipid and lipoprotein levels: optimal levels and lifestyle
The following levels of lipids and lipoproteins in women should be encouraged through lifestyle approaches: LDL-C 100 mg/dL, HDL-C 50 mg/dL,
triglycerides 150 mg/dL, and non–HDL-C (total cholesterol minus HDL) 130 mg/dL (Class I; Level of Evidence B).
Lipids: pharmacotherapy for LDL-C lowering, high-risk women
LDL-C–lowering drug therapy is recommended simultaneously with lifestyle therapy in women with CHD to achieve an LDL-C 100 mg/dL (Class I; Level of
Evidence A) and is also indicated in women with other atherosclerotic CVD or diabetes mellitus or 10-year absolute risk 20% (Class I; Level of Evidence B).
A reduction to 70 mg/dL is reasonable in very-high-risk women (e.g., those with recent ACS or multiple poorly controlled cardiovascular risk factors) with
CHD and may require an LDL-lowering drug combination (Class IIa; Level of Evidence B).
(Continued)
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Lipids: pharmacotherapy for LDL-C lowering, other at-risk women
LDL-C–lowering with lifestyle therapy is useful if LDL-C level is 130 mg/dL, there are multiple risk factors, and the 10-y absolute CHD risk is 10% to 20%
(Class I; Level of Evidence B).
LDL-C lowering is useful with lifestyle therapy if LDL-C level is 160 mg/dL and multiple risk factors even if 10-y absolute CHD risk is 10% (Class I;
Level of Evidence B).
LDL-C lowering with lifestyle therapy is useful if LDL 190 mg/dL regardless of the presence or absence of other risk factors or CVD (Class I; Level of
Evidence B).
In women 60 y of age and with an estimated CHD risk 10%, statins could be considered if hsCRP is 2 mg/dL after lifestyle modification and no acute
inflammatory process is present (Class IIb; Level of Evidence B).
Lipids: pharmacotherapy for low HDL-C or elevated non–HDL-C
Niacin or fibrate therapy can be useful when HDL-C is low (50 mg/dL) or non–HDL-C is elevated (130 mg/dL) in high-risk women after LDL-C goal is
reached (Class IIb; Level of Evidence B).
Diabetes mellitus
Lifestyle and pharmacotherapy can be useful in women with diabetes mellitus to achieve an HbA1C 7% if this can be accomplished without significant
hypoglycemia (Class IIa; Level of Evidence B).
reventive drug interventions
Aspirin: high-risk women
Aspirin therapy (75–325 mg/d) should be used in women with CHD unless contraindicated (Class I; Level of Evidence A).
Aspirin therapy (75–325 mg/d) is reasonable in women with diabetes mellitus unless contraindicated (Class IIa; Level of Evidence B).
If a high-risk woman has an indication but is intolerant of aspirin therapy, clopidogrel should be substituted (Class I; Level of Evidence B).
Aspirin: other at-risk or healthy women
Aspirin therapy can be useful in women 65 y of age (81 mg daily or 100 mg every other day) if blood pressure is controlled and benefit for ischemic
stroke and MI prevention is likely to outweigh risk of gastrointestinal bleeding and hemorrhagic stroke (Class IIa; Level of Evidence B) and may be reasonable
for women 65 y of age for ischemic stroke prevention (Class IIb; Level of Evidence B).
Aspirin: atrial fibrillation
Aspirin 75–325 mg should be used in women with chronic or paroxysmal atrial fibrillation with a contraindication to warfarin or at low risk of stroke
(1%/y or CHADS2 score of 2) (Class I; Level of Evidence A).
Warfarin: atrial fibrillation
For women with chronic or paroxysmal atrial fibrillation, warfarin should be used to maintain the INR at 2.0 to 3.0 unless they are considered to be at low
risk for stroke (1%/y or high risk of bleeding) (Class I; Level of Evidence A).
Dabigatran: atrial fibrillation
Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to permanent AF
and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal
failure (creatinine clearance 15 mL/min), or advanced liver disease (impaired baseline clotting function) (Class I; Level of Evidence B).
-Blockers
-Blockers should be used for up to 12 mo (Class I; Level of Evidence A) or up to 3 y (Class I; Level of Evidence B) in all women after MI or ACS with
normal left ventricular function unless contraindicated.
Long-term -blocker therapy should be used indefinitely for women with left ventricular failure unless contraindications are present (Class I; Level of
Evidence A).
Long-term -blocker therapy may be considered in other women with coronary or vascular disease and normal left ventricular function (Class IIb; Level of
Evidence C).
ACE inhibitors/ARBs
ACE inhibitors should be used (unless contraindicated) in women after MI and in those with clinical evidence of heart failure, LVEF 40%, or diabetes
mellitus (Class I; Level of Evidence A).
In women after MI and in those with clinical evidence of heart failure, an LVEF 40%, or diabetes mellitus who are intolerant of ACE inhibitors, ARBs should
be used instead (Class I; Level of Evidence B).
Note: ACE inhibitors are contraindicated in pregnancy and ought to be used with caution in women who may become pregnant.
Aldosterone blockade
Use of aldosterone blockade (e.g., spirololactone) after MI is indicated in women who do not have significant hypotension, renal dysfunction, or hyperkalemia
who are already receiving therapeutic doses of an ACE inhibitor and -blocker and have LVEF 40% with symptomatic heart failure (Class I; Level of
Evidence B).
LVEF indicates left ventricular ejection fraction; BMI, body mass index; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; ACE, angiotensin-converting
zyme; ARB, angiotensin receptor blocker; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CHD, coronary heart disease; CVD,
rdiovascular disease; ACS, acute coronary syndrome; hsCRP, high-sensitivity C-reactive protein; HbA1C, hemoglobin A1C; MI, myocardial infarction; CHADS2,
ngestive Heart Failure, Hypertension, Age, Diabetes, Prior Stroke; and INR, international normalized ratio.
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March 22, 2011:1404–23 Guidelines for the Prevention of CVD in Women—2011 Updateom the 2007 guidelines update were not searched because
consensus by the expert panel members that data remained
sufficient for modification (ie, menopausal therapy, antiox-
ants, and folic acid supplementation). Some topics were not
cluded in the systematic search if they were covered in
cent guidelines (e.g., treatment of atrial fibrillation for
roke prevention) (10).
vidence Rating and
ecommendation Procedures
ubcommittees were organized by subtopic and were charged
ith preparation of summary evidence tables based on the
dated literature review. These tables were then reviewed in
ries of conference calls, after which the subcommittee
odified or retained the current recommendation on the basis
the discussions. Each recommendation was assigned both
strength of recommendation (Class I, IIa, IIb, or III) and a
evel of Evidence (A, B, or C) as outlined in Table 3. The
dated recommendations were voted on by the expert panel
individual ballot to determine by a majority vote the final
ting of evidence, the strength of the recommendation, and
s wording. Further minor modifications to text and clinical
commendations were based on peer review comments and
sponsor reviews. The guidelines were then finalized and
proved by the expert panel (Table 4).
ost-Effectiveness
ost-effectiveness analyses reviewed were published between
00 and 2010, focusing on randomized controlled trials and
servational studies of omega-3 use, dietary intake,
-blocker and aspirin therapy, and management of obesity,
oking, and hypertension in secondary and primary preven-
on of CVD (108–125). Few of these studies included
nder-stratified or gender-specific analyses (119,122); how-
er, some cost-effectiveness analyses with Markov or sim-
ppendix. Specific Dietary Intake Recommendations for Women
Nutrient Serving
uits and vegetables 4.5 cups/d 1 cup raw
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sh 2/wk 3.5 oz, coo
ber 30 g/d (1.1 g/10 g carbohydrate) Bran cerea
hole grains 3/d 1 slice bre
products
gar 5/wk (450 kcal/wk from
sugar-sweetened beverages)
1 tablespoo
ts, legumes, and seeds 4/wk 1/3 cup or
butter, 2
turated fat 7%/total energy intake Found in fr
sour cre
olesterol 150 mg/d Found in a
cohol 1/d 4 oz wine,
dium 1,500 mg/d
ans-fatty acids 0 0
Note: The recommended serving amounts are based on a 2,000-kcal diet, a
Note for Vitamin D: It is expected that ongoing research regarding the role of vi
ht on this issue for future versions of this guideline (142).ation modeling presented gender-specific or women-only
ta (126–138).
Often the cost inputs and methodologies were insufficiently
scribed or used resource consumption as a surrogate for
st. On the basis of these analyses, aspirin appears cost-
fective in women 65 years of age with moderate to severe
VD risk (133–135). Antihypertensive treatments and smok-
g cessation treatments appear cost-effective for women
26–132). Weight management approaches, including drug
erapy and gastric bypass surgery, appear effective for
eight loss but add costs, with decision analytic approaches
ting favorable cost-effective ratios in younger and middle-
ed obese women (123,137,138).
The expert panel emphasized the need for more cost-
fective analyses according to gender. Consistent with a
cent Institute of Medicine report on women’s health re-
arch, the expert panel recommends adequate participation
women and reporting of gender-stratified analyses in
alth research (139). The panel also emphasized the need for
porting of gender-specific analyses for both efficacy and
verse effects of preventative interventions to inform the
velopment of future gender-specific guidelines.
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